Enhancing the Anti-Tumor Activity of ErbB Blockers With Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

doi 10.21236/ada458444
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Scoparone Exerts Anti-Tumor Activity Against DU145 Prostate Cancer Cells via Inhibition of STAT3 Activity

PLoS ONE
Multidisciplinary
2013English

Identification of Prostate Cancer-Related Genes Using Inhibition of NMD in Prostate Cancer Cell Lines

2007English

Histone Demethylase KDM7A Controls Androgen Receptor Activity and Tumor Growth in Prostate Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

Vascular Histone Deacetylation by Pharmacological HDAC Inhibition

Genome Research
Genetics
2014English

The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2

PLoS ONE
Multidisciplinary
2013English

Beefing Up Prostate Cancer Therapy With Performance-Enhancing (Anti-) Steroids

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

Methylseleninic Acid Inhibits HDAC Activity in Diffuse Large B-Cell Lymphoma Cell Lines

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

Enhancing Anti-Prostate Cancer Immunity Through OX40 Engagement

2006English

Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy